A prospective, observational web‐based cohort assessing the safety of safety profile of the new antidiabetic agents glucagon‐like peptide‐1 agonists and dipeptidyl peptidase‐4 inhibitors in daily practice
Latest Information Update: 02 Sep 2020
At a glance
- Drugs Exenatide (Primary) ; Linagliptin (Primary) ; Liraglutide (Primary) ; Saxagliptin (Primary) ; Sitagliptin (Primary) ; Vildagliptin (Primary)
- Indications Type 2 diabetes mellitus
- Focus Adverse reactions
- 02 Sep 2020 New trial record
- 27 Aug 2020 Results published in the Pharmacoepidemiology and Drug Safety